Literature DB >> 17365278

Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro.

Tathagata Dutta1, Hrushikesh B Agashe, Minakshi Garg, Prahlad Balakrishnan, Prahlad Balasubramanium, Madhulika Kabra, Narendra K Jain.   

Abstract

Cells of the mononuclear phagocytic system, in particular monocytes/macrophages (Mo/Mac) serve as a reservoir for human immunodeficiency virus (HIV) and are believed to be responsible for its dissemination throughout the body and especially into the brain. Treatment of HIV infection, therefore, must reach these cells in addition to the lymphocytes. The purpose of the present study is to develop poly(propyleneimine) (PPI) dendrimer-based nanocontainers for targeting of efavirenz (EFV) to Mo/Mac. Fifth generation PPI dendrimer, t-Boc-glycine conjugated PPI dendrimer (TPPI) and mannose conjugated dendrimers were synthesized and characterized. While the haemolytic activity and cytotoxicity of PPI dendrimer was found to be very high, the toxicity of t-Boc-glycine conjugated dendrimer and mannose conjugated dendrimers were found to be negligible. The entrapment efficiency of mannose conjugated dendrimer was found to be 47.4%, followed by that of PPI dendrimer (32.15%) and t-Boc-glycine conjugated dendrimer (23.1%). The in vitro drug release profile shows that while PPI dendrimer releases the drug by 24 h, the dendrimer-based nanocontainers prolong the release rate up to 144 h (83 +/- 0.4% in case of t-Boc-glycine conjugated dendrimer and 91 +/- 0.3% in mannose conjugated dendrimer). The cellular uptake of EFV was found to be both concentration and time dependent. Significant increase in cellular uptake of EFV by Mo/Mac cells were observed in case of mannose conjugated dendrimer which is 12 times higher than that of free drug and 5.5 times higher than that of t-Boc-glycine conjugated dendrimer. While mannose conjugated dendrimer was taken up by the lectin receptors of the cells, phagocytosis of t-Boc-glycine conjugated dendrimer might be responsible for its enhanced uptake. Results suggest that the proposed carriers hold potential to increase the efficacy and reduce the toxicity of antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17365278     DOI: 10.1080/10611860600965914

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  34 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

2.  Surface-engineered dendrimeric nanoconjugates for macrophage-targeted delivery of amphotericin B: formulation development and in vitro and in vivo evaluation.

Authors:  Keerti Jain; Ashwni Kumar Verma; Prabhat Ranjan Mishra; Narendra Kumar Jain
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

3.  Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers.

Authors:  Rohit B Kolhatkar; Peter Swaan; Hamidreza Ghandehari
Journal:  Pharm Res       Date:  2008-04-26       Impact factor: 4.200

Review 4.  Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.

Authors:  Marina A Dobrovolskaia; Parag Aggarwal; Jennifer B Hall; Scott E McNeil
Journal:  Mol Pharm       Date:  2008-05-30       Impact factor: 4.939

Review 5.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

6.  Microcalorimetric method to assess phagocytosis: macrophage-nanoparticle interactions.

Authors:  M H D Kamal Al-Hallak; Muhammad Khan Sarfraz; Shirzad Azarmi; M H Gilzad Kohan; Wilson H Roa; Raimar Löbenberg
Journal:  AAPS J       Date:  2010-11-06       Impact factor: 4.009

Review 7.  Design and creativity in synthesis of multivalent neoglycoconjugates.

Authors:  Yoann M Chabre; René Roy
Journal:  Adv Carbohydr Chem Biochem       Date:  2010       Impact factor: 12.200

Review 8.  Surface modifications of nanocarriers for effective intracellular delivery of anti-HIV drugs.

Authors:  Simi Gunaseelan; Krishnan Gunaseelan; Manjeet Deshmukh; Xiaoping Zhang; Patrick J Sinko
Journal:  Adv Drug Deliv Rev       Date:  2009-11-24       Impact factor: 15.470

Review 9.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 10.  Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies.

Authors:  Benson J Edagwa; Tian Zhou; JoEllyn M McMillan; Xin-Ming Liu; Howard E Gendelman
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.